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Abstract
Background: Genetic and epidemiological evidence suggests an inverse association between B-type natriuretic peptide
(BNP) levels in blood and risk of type 2 diabetes (T2D), but the prospective association of BNP with T2D is uncertain, and it is
unclear whether the association is confounded.
Methods and Findings: We analysed the association between levels of the N-terminal fragment of pro-BNP (NT-pro-BNP) in
blood and risk of incident T2D in a prospective case-cohort study and genotyped the variant rs198389 within the BNP locus
in three T2D case-control studies. We combined our results with existing data in a meta-analysis of 11 case-control studies.
Using a Mendelian randomization approach, we compared the observed association between rs198389 and T2D to that
expected from the NT-pro-BNP level to T2D association and the NT-pro-BNP difference per C allele of rs198389. In
participants of our case-cohort study who were free of T2D and cardiovascular disease at baseline, we observed a 21% (95%
CI 3%–36%) decreased risk of incident T2D per one standard deviation (SD) higher log-transformed NT-pro-BNP levels in
analysis adjusted for age, sex, body mass index, systolic blood pressure, smoking, family history of T2D, history of
hypertension, and levels of triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. The
association between rs198389 and T2D observed in case-control studies (odds ratio=0.94 per C allele, 95% CI 0.91–0.97)
was similar to that expected (0.96, 0.93–0.98) based on the pooled estimate for the log-NT-pro-BNP level to T2D association
derived from a meta-analysis of our study and published data (hazard ratio=0.82 per SD, 0.74–0.90) and the difference in
NT-pro-BNP levels (0.22 SD, 0.15–0.29) per C allele of rs198389. No significant associations were observed between the
rs198389 genotype and potential confounders.
Conclusions: Our results provide evidence for a potential causal role of the BNP system in the aetiology of T2D. Further
studies are needed to investigate the mechanisms underlying this association and possibilities for preventive interventions.
Please see later in the article for the Editors’ Summary.
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B-type natriuretic peptide (BNP) is a hormone released from the
myocardium in response to increased mechanical strain in order to
maintain cardiac function by mediating vasodilation, natriuresis,
and anti-fibrotic effects [1]. In addition to cardiovascular effects,
BNP also has lipolytic activity in human adipose tissue [2]. This—
together with the observation that levels of BNP or the inactive
fragment of its pro-hormone (N-terminal fragment of pro-BNP
[NT-pro-BNP]) are consistently decreased in individuals with
obesity, insulin resistance, and type 2 diabetes (T2D) in cross-
sectional studies—raises the possibility of a role of BNP in the
aetiology of metabolic disease [3,4].
Additional evidence suggests a specific link between a common
genetic variant (rs198389) within the BNP gene locus (NPPB) and
risk of T2D [5]. Importantly, a variant in high linkage
disequilibrium with rs198389 (rs632793 within the adjacent locus
NPPA, r
2=0.87) was shown to be associated with BNP/NT-pro-
BNP levels in a meta-analysis of four cohorts comprising more
than 14,000 individuals; the allele associated with a lower T2D risk
was associated with higher BNP/NT-pro-BNP levels [6]. This
might point to a potential beneficial effect of BNP hormone in the
aetiology of T2D.
However, there is also evidence to suggest reverse causality, with
BNP/NT-pro-BNP levels being a consequence rather than a cause
of T2D. Short-term increase of insulin levels was shown to
decrease NT-pro-BNP levels in non-diabetic individuals with
ischemic heart disease [7]. Additionally, obesity somehow impairs
the BNP/NT-pro-BNP response [8–10]. Both mechanisms might
lead to an overestimation of the association between BNP/NT-
pro-BNP and T2D risk in cross-sectional analysis.
So far, to our knowledge, only one prospective study has
examined the association between BNP/NT-pro-BNP levels and
incident T2D [11]. However, in this study 5% of participants
reported cardiovascular disease at baseline. Individuals with
cardiovascular disease show up to 100-fold increased blood levels
of BNP/NT-pro-BNP compared to healthy individuals, which
might lead to a distorted estimate of the BNP/NT-pro-BNP to
T2D association.
The aim of our study was to investigate the causal role of BNP
in the aetiology of T2D by using a Mendelian randomization
approach. Therefore, we analysed the association between NT-
pro-BNP levels and incident T2D in a large prospective case-
cohort study excluding individuals with baseline T2D and
cardiovascular disease. We then extended existing genetic data
by de novo genotyping of the variant rs198389 in three T2D case-
control studies and by using unpublished data from the Diabetes
Genetics Replication and Meta-Analysis+(DIAGRAM+) consor-
tium, together comprising 15,638 T2D cases and 47,559 controls.
Finally, we estimated the expected association between rs198389
and T2D risk based on the NT-pro-BNP to T2D association and
the difference in NT-pro-BNP levels associated with each
rs198389 C allele, and performed instrumental variable analysis
to calculate the unconfounded effect size of NT-pro-BNP levels on
T2D risk.
Methods
Ethics Statement
The Cambridgeshire and the ADDITION-Ely case-control
studies received ethical approval from the Cambridge Local
Research Ethics Committee, and participants provided informed
consent. The EPIC-Norfolk cohort study was approved by the
Norwich Local Research Ethics Committee.
Study Populations
We used three T2D case-control studies (Cambridgeshire,
ADDITION-Ely, and Norfolk Diabetes) and the population-based
EPIC-Norfolk cohort for genetic analysis, and the EPIC-Norfolk
cohort for blood-based analysis. De novo genotyping of the variant
rs198389 was performed in the three case-control studies
comprising 7,508 cases and 8,572 controls, and in the total
EPIC-Norfolk cohort. Additionally, we used unpublished genetic
data from T2D case-control sets of the DIAGRAM+ consortium.
Cambridgeshire case-control study. The Cambridgeshire
case-control study is a population-based study of T2D cases, aged
45–76 y, and age- and sex-matched controls. Cases were
randomly selected from general practitioner diabetes registers in
Cambridgeshire, UK, and T2D was defined as onset of diabetes
after the age of 30 y and without insulin use in the first year after
diagnosis [12]. Controls were recruited at random from the same
population sampling frames, and individually matched to cases for
age, sex, and general practitioner practice. Diabetes was excluded
in controls by medical record search and by a glycated
haemoglobin measurement of less than 6%. In the current
analyses, we include 506 cases and 512 controls, representing all
white Europeans who had DNA available and information on
body mass index (BMI).
ADDITION-Ely case-control study. Previously undiag-
nosed prevalent cases of T2D, defined using World Health
Organization oral glucose tolerance testing criteria, were identified
via a population-based stepwise screening strategy among 40- to
69-y olds participating in the UK Cambridge arm of the
ADDITION study. Current analyses include 765 white
European men and women who had DNA available and
information on BMI [13]. Controls were identified from the
Medical Research Council (MRC) Ely study, a population-based
cohort of white European men and women aged 35 to 79 y
without diagnosed diabetes and from a similar sampling frame as
the cases [14]. Based on WHO oral glucose tolerance testing
criteria, participants were confirmed as controls (n=1,606) or
classified as cases (n=91).
Norfolk Diabetes case-control study. The Norfolk
Diabetes case-control study is a study of men and women with
T2D in Norfolk, UK. All T2D patients identified through general
practice diabetes registers in Norfolk and local hospital diabetes
clinic and retinal screening programme patient registers were
invited to participate; a total of 6,146 white European cases were
included in the current analyses, aged 31 to 98 y. Participants with
insulin use during the first year of diagnosis, and those with cystic
fibrosis, chronic pancreatitis, or long-term steroid use were
excluded from the study. The 6,454 controls free of known
diabetes at baseline and during follow-up were randomly selected
from participants of the EPIC-Norfolk cohort, who are described
in more detail below.
Case-control dataset of the DIAGRAM+ consortium. We
used the unpublished pooled effect estimate of rs198389 on T2D
risk from the published dataset of eight case-control studies
comprising 8,130 T2D patients and 38,987 controls of European
descent reflecting the total stage 1 dataset of the DIAGRAM+
consortium (for details of the eight cohorts [Wellcome Trust Case
Control Consortium, Diabetes Genetics Initiative, Finland-US
Investigation of NIDDM Genetics, deCODE Genetics, Diabetes
Gene Discovery Group, Cooperative Health Research in the
Region of Augsburg, Rotterdam Study, and European Special
BNP and Diabetes
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material Table 1 of [15]). All stage 1 samples of DIAGRAM+
had genome-wide association data available and hence allowed in
silico analysis. The effective sample size was n=22,044.
Association estimates of the eight individual studies were
combined by fixed-effects, additive-model meta-analysis using
the inverse-variance method.
EPIC-Norfolk cohort study. EPIC-Norfolk is a prospective
cohort study in which men and women aged 39 to 79 y were
recruited from general practices in the Norfolk region, UK. Full
details of the population are reported elsewhere [16]. Between
1993 and 1997, 25,639 participants completed a health and
lifestyle questionnaire and a health examination; non-fasting blood
samples were taken for analysis of laboratory markers. Details of
assessment of baseline variables are described elsewhere [17,18].
DNA from stored baseline blood samples was available for
genotyping in 21,121 participants.
We used a case-cohort study for incident T2D nested within
the total EPIC-Norfolk cohort to assess the association between
NT-pro-BNP levels and incident T2D. All individuals with any
evidence of diabetes at baseline were excluded. Prevalent diabetes
was identified on the basis of baseline self-report of a history of
diabetes, doctor-diagnosed diabetes, diabetes drug use, or
evidence of diabetes after baseline with a date of diagnosis
earlier than the baseline recruitment date. Ascertainment of
incident T2D in the EPIC-Norfolk cohort used multiple sources
of evidence including self-report (self-reported history of T2D,
doctor-diagnosed T2D, diabetes drug use), linkage to primary
care registers, secondary care registers, hospital admissions, and
mortality data. To increase the specificity of the case definition,
we sought further evidence for all cases with information on
incident T2D from two independent sources at a minimum,
including individual medical record review and diabetes register
searches. Follow-up was censored at the date of diagnosis, 31
December 2007, or the date of death, whichever occurred first.
Individuals without stored blood or without information on
reported diabetes status were excluded, leaving a total of 661
incident T2D cases.
In our case-cohort design we randomly selected a subcohort of
877 individuals from those with available stored blood. By design,
this subcohort also included a random set of 24 individuals who
had developed incident T2D during follow-up, i.e., the case-cohort
set included 661 incident T2D cases and 853 non-cases. For this
analysis we excluded individuals with history of cardiovascular
disease defined by self-reported myocardial infarction or stroke
(n=88), individuals without NT-pro-BNP measure (n=132), and
individuals without information on covariates for multivariable
analysis (n=114), leaving 440 incident T2D cases and 740 non-
cases.
In addition, we used 6,454 participants randomly selected from
the total EPIC-Norfolk cohort without known or incident diabetes
and available baseline DNA samples as controls in the Norfolk
Diabetes case-control study. Of these, 650 were also non-cases in
the subcohort and were used to examine the association between
the variant rs198389 and NT-pro-BNP levels.
Measurement of Serum NT-pro-BNP Levels
NT-pro-BNP was measured on stored baseline serum samples
in the T2D case-cohort study of the EPIC-Norfolk cohort (440
cases/740 non-cases) using an electrochemiluminescence immu-
noassay on the Elecsys 2010 Immunoanalyzer (Roche Diagnos-
tics). The assay has an effective measuring range of 5–35,000 pg/
ml. The median within-run coefficient of variation was 4.5% at a
concentration of 129 pg/ml and 1.0% at 4,538 pg/ml. The
overall coefficients of variation throughout the study were 4.6%
and 4.8% at the same concentrations.
Genotyping
We genotyped the rs198389 genetic variant within the
‘‘natriuretic peptide precursor B’’ locus, reported to be associated
with T2D risk in a candidate gene study and replicated in a meta-
analysis [5,19]. For the total EPIC-Norfolk cohort, genotyping was
performed by using an iPLEX (Sequenom) platform. For the three
case-control studies, genotyping was performed with Custom
TaqMan SNP Genotyping Assays (Applied Biosystems). The
variant passed quality-control criteria (call rate .95% and
duplicate concordance .98% assessed in approximately 1% of
each study sample) and was in Hardy-Weinberg equilibrium (p-
values.0.05) in all cohorts. Allele frequencies were consistent with
those reported for the CEU population (US residents with
northern and western European ancestry of the Centre d’Etude
du Polymorphisme Humain) of the HapMap database (http://
hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap28_B36/).
Statistical Analyses
Association of BNP levels with T2D risk. The prospective
association between log-transformed NT-pro-BNP levels and
incident T2D was examined in the case-cohort study of the
EPIC-Norfolk cohort, baseline characteristics of which are shown
in Table S1. We used Prentice-weighted Cox models (with age as
underlying time scale) to account for the case-cohort design [20].
We did not observe evidence for a statistical departure from
linearity in the NT-pro-BNP level to T2D association when
calculating the difference in log likelihood for modelling quartiles
of log-transformed NT-pro-BNP levels as a continuous term
against categories (p=0.11, data not shown). Hazard ratios (HRs)
are presented, representing the effect of a change of one sex-
specific standard deviation (SD) in log-transformed NT-pro-BNP
levels. We combined our estimate with the results of a study that
was published while our work was ongoing [11], applying a fixed-
effects meta-analysis model as no evidence for heterogeneity
between the two studies was observed. In the original report of the
additional study, NT-pro-BNP was cubic-root-transformed for
analysis. For our meta-analysis we used estimates that were re-
calculated with log-transformation instead.
Association of rs198389 with BNP levels and cardio-
metabolic traits. The association between the variant
rs198389 and log-transformed NT-pro-BNP levels was examined
in the EPIC-Norfolk subcohort, excluding participants with
incident T2D. As described previously [6], residuals were
obtained using sex-specific regression models in which log-
transformed NT-pro-BNP concentrations were adjusted for age,
BMI, and hypertension. We observed an additive effect for the
association between the rs198389 alleles and serum NT-pro-BNP
levels, and genetic variant was coded as 0, 1, and 2 on the basis of
the number of the serum NT-pro-BNP-increasing alleles (C
alleles).
We identified published studies reporting levels of BNP/NT-
pro-BNP by genetic variants within the BNP locus by performing a
systematic literature search in PubMed 2.0 (US National Library
of Medicine) using the search terms ‘‘single nucleotide polymor-
phism’’ and ‘‘natriuretic peptide’’ (last search conducted 1
December 2010). Review of 60 identified abstracts revealed four
studies that reported BNP/NT-pro-BNP levels by BNP genotype.
We excluded one study that examined a population of non-
European descent [21] and two studies that examined individuals
with advanced cardiac disease [5,22]. One study was a meta-
analysis of four cohorts of European descent that reported the
BNP and Diabetes
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disequilibrium with rs198389, r
2=0.87) and BNP or NT-pro-
BNP levels [6]. We used a random effect model to update this
meta-analysis when including our results, as we observed evidence
for significant heterogeneity across studies.
One key assumption of Mendelian randomization is that the
genetic variants do not show pleiotropic effects, i.e., are not
associated with other diabetes risk factors. To test this assumption
the association between the variant rs198389 and cardio-
metabolic traits was examined in participants of the EPIC-Norfolk
cohort study without prevalent T2D (maximum n=19,746).
Association between rs198389 and T2D risk. Logistic
regression analysis was used to calculate odds ratios (ORs) for the
association between rs198389 and T2D, adjusting for age, sex, and
BMI unless indicated otherwise. As observed for the association
with NT-pro-BNP levels, there was evidence for an additive effect
of rs198389 on T2D risk within our three case-control studies,
with an OR of 0.91 (95% CI 0.84–0.99) and 0.87 (95% CI 0.78–
0.97) for the CT and the CC genotype compared to the TT
genotype, and with the lowest p-value (p=0.007) for the additive
model compared to dominant (p=0.008) and recessive (p=0.10)
models. ORs of the three case-control studies (Cambridgeshire,
ADDITION-Ely, and Norfolk Diabetes, together comprising
7,508 cases and 8,572 controls) were combined with the pooled
estimate of the DIAGRAM+ consortium comprising 8,130 T2D
cases and 38,987 controls of European descent [15] and seven
additional case-control studies of an existing meta-analysis
comprising 7,744 T2D cases and 10,339 controls of European
descent [19] by applying a fixed-effects meta-analysis model. The
latter meta-analysis was identified in a systematic literature
research in PubMed 2.0 using the search terms ‘‘single
nucleotide polymorphism’’, ‘‘natriuretic peptide’’, and ‘‘diabetes
mellitus’’ (last search conducted 1 December 2010). Review of five
identified abstracts revealed two meta-analyses on the effect of the
variant rs198389 on T2D in cohorts of European descent, one of
which was the update [19] of the other one [5]. We excluded five
of the 12 case-control studies reported in the meta-analysis [19]
because they were part of DIAGRAM+ (Diabetes Genetics
Initiative, Finland-US Investigation of NIDDM Genetics, and
deCODE Genetics) or because they were earlier versions of our
case-control studies with smaller sample sizes (Norfolk Diabetes
and Cambridgeshire).
The concept of Mendelian randomization is used to test
causality of associations between risk factors and outcomes [23].
Genetic variants are randomly allocated during gamete formation,
and hence are not subject to environmental influences or reverse
causation. Accordingly, genetic variants that are associated with
the risk factor can be used as instrumental variables to calculate an
estimate of the magnitude of association free of the problems of
confounding and reverse causality. We used the estimates of the
association of the genetic variant rs198389 with serum NT-pro-
BNP levels (see A in Figure 1) and of the association of serum NT-
pro-BNP levels with T2D (see B in Figure 1) to calculate an
approximate expected effect of the genetic variant on T2D,
assuming an aetiological role of BNP levels for T2D:
Expected effect~exp difference in serum log ð
{transformed NT{pro
{BNP levels by genotype|ln HR ðÞ Þ ,
where HR is the risk of incident T2D per SD of log-transformed
NT-pro-BNP level. The standard error for the expected effect size
was calculated using a Taylor series approximation [24]. Finally,
we also performed an instrumental variable analysis using a logistic
control function estimator to estimate the unconfounded effect size
of log-transformed NT-pro-BNP levels on T2D risk using
individuals of the T2D case-cohort study of the EPIC-Norfolk
cohort who also had the rs198389 genotype available (n=623
non-cases, n=371 cases). As previously described [25], in this
analysis the variation of the potentially causal risk factor NT-pro-
BNP that is determined by the instrument (rs198389) is related to
the risk of T2D by applying a two-stage analysis. In the first stage,
the observational association between genotype and log-trans-
formed NT-pro-BNP was estimated in linear regression; in the
second stage the predicted values and residuals from this model
were included as covariates in a logistic regression model with
T2D as the outcome.
All analyses were performed using STATA version 10.1
(Statacorp).
Results
Association of B-Type Natriuretic Peptide Levels with
Type 2 Diabetes Risk
NT-pro-BNP levels were inversely associated with risk of T2D
in age- and sex-adjusted analysis of the EPIC-Norfolk case-cohort
(440 cases/740 controls), with a HR of 0.82 (95% CI 0.69–0.97,
p=0.02) for the difference of 1 SD in log-transformed NT-pro-
BNP levels. In multivariable analysis adjusting for age (underlying
time scale), sex, family history of diabetes, systolic blood pressure,
BMI, current cigarette smoking, levels of high-density lipoprotein
and low-density lipoprotein cholesterol and triglycerides, and
history of hypertension, every increase of one SD in log-
transformed NT-pro-BNP levels was associated with a 21%
decreased risk of T2D (HR=0.79, 95% CI 0.64–0.97, p=0.02),
with similar results in men (HR=0.82, 95% CI 0.57–1.18) and
women (HR=0.76, 95% CI 0.60–0.96) and without evidence for
a significant sex by NT-pro-BNP interaction (p=0.48).
We combined our result with the estimate of the FINRISK97
study, which did not exclude baseline cardiovascular disease [11],
since there was no evidence for heterogeneity across the two
studies (I
2=0%, p=0.74). The difference of one SD in log-
transformed NT-pro-BNP levels was associated with an 18%
reduced risk of T2D (HR=0.82 95% CI 0.74–0.90, p=0.0001) in
the meta-analysis comprising 857 T2D cases and 8,150 non-cases
(Figure 2).
Association of rs198389 with B-Type Natriuretic Peptide
Levels and Cardio-Metabolic Traits
In the EPIC-Norfolk subcohort excluding participants with
incident T2D (final n with available genotype=650), each copy of
the C allele of rs198389 was associated with an increase of 0.23 SD
(95% CI 0.12–0.34, p,0.001) in log-transformed NT-pro-BNP
levels. We combined our result with a previously published meta-
analysis [6], comprising in total 15,123 individuals (Figure 3). In
pooled analysis we observed an increase of 0.22 SD (95% CI 0.15–
0.29, p,0.001) in log-transformed BNP/NT-pro-BNP levels per
allele, with estimates ranging from 0.13 to 0.30 SD and evidence
for significant heterogeneity across studies (I
2=86.1%, p,0.001).
Heterogeneity was driven by the estimate of the Malmoe study
(from [6]); when excluding this study from the meta-analysis, the
pooled estimate as well as the calculated expected effect of
rs198389 on T2D risk did not change markedly (data not shown).
In the total EPIC-Norfolk cohort excluding participants with
prevalent T2D there was no evidence for a significant association
between the genotype of rs198389 and cardio-metabolic charac-
teristics including BMI; waist circumference; systolic and diastolic
BNP and Diabetes
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lipoprotein cholesterol; triglycerides; alcohol consumption; levels
of serum uric acid, serum creatinine, and C-reactive protein;
history of hypertension; smoking; and family history of diabetes (n
between 15,049 and 19,746), although there was a borderline
significant association of lower systolic and diastolic blood pressure
and a lower rate of history of hypertension with the C allele of
rs198389 (all p=0.07; Table S2).
Association between rs198389 and Type 2 Diabetes Risk
We observed a significant association between the variant
rs198389 and risk of T2D in a meta-analysis of our three case-
control studies, DIAGRAM+, and seven previously published
case-control studies comprising a total of 23,382 T2D cases and
57,898 controls (Figure 4), with an OR of 0.94 (95% CI 0.91–0.97,
Figure 1. Mendelian randomization approach for the association between BNP and T2D. The observed association between BNP
genotype rs198389 and risk of T2D is compared with that expected based on the genotype to peptide level association and the peptide level to T2D
association.
doi:10.1371/journal.pmed.1001112.g001
Figure 2. Meta-analysis of the association between serum NT-
pro-BNP levels and incident T2D.
doi:10.1371/journal.pmed.1001112.g002
Figure 3. Meta-analysis of the association between the variant
rs198389 and serum BNP levels. Effect estimates (beta) are from
linear regression assuming an additive model and are shown on the SD
scale. Asterisk indicates that proxy rs632793 was used.
doi:10.1371/journal.pmed.1001112.g003
BNP and Diabetes
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heterogeneity across studies (I
2=0%, p=0.64).
We used the estimates of the association between (a) the variant
rs198389 and NT-pro-BNP levels and (b) NT-pro-BNP levels and
risk of T2D to calculate an approximate expected effect of the
variant rs198389 on T2D (Figure 1). The expected effect size was
0.96 (95% CI 0.93–0.98) per C allele of rs198389, which was
similar to that observed in the case-control studies.
To estimate the unconfounded association of NT-pro-BNP levels
withT2Drisk we performed an instrumentalvariable analysis inthe
EPIC-Norfolk case-cohort data. We observed an OR for T2D of
0.89 (95% CI 0.37–2.16) per one SD increase in log-transformed
NT-pro-BNP levels, which was not statistically significant (p=0.80)
because of thesmall samplesizeavailablefor this analysis. However,
it is consistent in size and direction with the estimate of the main
observational association analysis (HR=0.82, 95% CI 0.74–0.90).
Discussion
In a large prospective cohort free of baseline T2D and
cardiovascular disease, we demonstrate an inverse association
between NT-pro-BNP levels and risk of incident T2D indepen-
dently of several established risk factors. In a Mendelian
randomization approach we integrated meta-analysed risk esti-
mates of the triangulation between genetic variant rs198389, NT-
pro-BNP levels, and T2D risk and provide evidence for a potential
causal, protective role of the BNP hormone system in the aetiology
of T2D. The association between the variant rs198389 and risk of
T2D expected from the NT-pro-BNP to T2D association and the
difference in NT-pro-BNP levels per rs198389 allele was similar to
that observed in T2D case-control studies, and instrumental
variable analysis suggested an effect size of genetically increased
NT-pro-BNP levels on risk for T2D consistent with that found in
the ordinary regression analysis of observational cohort studies.
Our results for a prospective cohort on the inverse association
between NT-pro-BNP levels and T2D risk are in line with
previous cross-sectional data [3] and a very recently published
analysis of the FINRISK97 study in which the prospective
association of 31 biomarkers, including BNP and NT-pro-BNP,
with T2D was examined [11]. The association of NT-pro-BNP
with T2D risk was stronger in our study compared to in
FINRISK97, but we did not detect significant heterogeneity in a
meta-analysis of both studies. The stronger association seen in our
study might be due to our exclusion of prevalent cardiovascular
disease, which leads to a release of NT-pro-BNP into circulation
and hence might dilute the association of NT-pro-BNP levels with
T2D in FINRISK97. We did not assess cardiac function in our
study and used self- report to exclude prevalent cardiovascular
disease. Given that latent left-ventricular dysfunction is common in
elderly populations [26], we still may have underestimated the
association of NT-pro-BNP with T2D, and in consequence,
expected and observed associations between rs198389 and T2D
might indeed be identical.
Although we used a prospective cohort with a long follow-up
time and multivariable adjustment, bias by reverse causality or
residual confounding cannot be completely ruled out. For
instance, disease processes such as insulin resistance might precede
the diagnosis of T2D for many years [27] and may also affect NT-
pro-BNP levels. However, the novelty of our study is the
integration of new and existing data in a Mendelian randomiza-
tion approach, which allows a more definite conclusion on the
likelihood of the causal nature of associations observed, similar to
randomized controlled trials, because randomly allocated genetic
variants are not expected to be subject to confounding or reverse
effects [23]. We used a genetic variant within the BNP gene locus
(rs198389) for which a significant association with risk of T2D was
previously reported [5,19]. These earlier studies proposed a
recessive model for the effect of rs198389 on T2D risk, based on
Figure 4. Meta-analysis of the association between the variant rs198389 and risk of T2D. Adjusted for age, sex, and BMI except for
MONICA (additionally adjusted for three centres) and UK (unadjusted).
doi:10.1371/journal.pmed.1001112.g004
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levels of statistical significance for the association with T2D. We
used an additive model, though, which is unequivocally supported
by observed associations with hormone levels, and thus might
better reflect underlying physiology, assuming a linear relation
between hormone levels and effects. Exceeding the sample size of
the previous meta-analysis by almost 32,000, individuals including
11,000 T2D cases, we have good statistical power to reliably
estimate the risk of T2D associated with the rs198389 genotype.
Accordingly, our estimation of the genotype to NT-pro-BNP level
association is also based on more than 15,000 individuals.
An important assumption of Mendelian randomization is that
the genetic variant must mediate its effect on outcome only via the
risk factor, i.e., the genetic variant shows no pleiotropic effects.
Although this assumption cannot be proven formally in practice
because of incomplete knowledge of the underlying biology, we
did not observe significant associations between the variant
rs198389 and potential confounders in an analysis of about
20,000 individuals. Notably, rs632793, which was used as a proxy
for rs198389 in some of our analyses, is not only associated with
NT-pro-BNP levels but also with atrial natriuretic peptide (ANP)
levels. Stimuli for hormone secretion are similar for ANP and
BNP, and both hormones share the same receptors for mediating
physiological effects. ANP and BNP hormone levels are highly
correlated (r=0.71), and coordinate regulation at the genetic level
has been proposed [6,11]. This strong correlation makes it difficult
to disentangle the distinct effects of ANP and BNP. The possible
association between rs198389 and blood pressure might be
mediated through ANP, which was shown to be robustly
associated with blood pressure in humans [6], but there might
also be a weak effect of BNP on blood pressure. However, a
potential association with blood pressure would not affect our
main conclusions, as it is unlikely that hypertension is on the causal
pathway for development of T2D.
Additionally, there is evidence in support of BNP mediating the
observed association between rs198389 and T2D rather than
ANP. First, the proxy rs632793 is associated with ANP levels, but
the association with BNP levels is almost three times stronger [6].
Second, the variant rs198389 is within the promoter region of
the BNP gene and has been shown to influence promoter activity
in experimental studies [5], which suggests that rs198389 is
functionally relevant for regulating BNP hormone levels. Third,
preliminary analysis on a genetic variant (rs5068) within the ANP
locus that has an effect on BNP levels similar to that of rs198389
and an almost 3-fold stronger effect on ANP levels also showed an
effect on T2D risk similar to that of rs198389 (data not shown).
Given that the effects of ANP and BNP levels on T2D risk are
similar [11], the latter suggests that the association between rs5068
and T2D is also mediated through BNP rather than through ANP
levels. However, because of the limited specificity of our
instrumental variable, we cannot rule out a role of ANP in the
development of T2D. Analysis in other ethnic groups with a
different linkage disequilibrium structure between ANP and BNP
genotypes might help clarify the distinct role of both hormone
systems in T2D.
There are additional limitations to this study. Our cohorts
comprised only individuals of European descent, which limits
generalisability of our findings to other ethnicities. Furthermore,
we cannot provide conclusive evidence for the underlying
mechanism of the association between the BNP hormone system
and T2D. Further experimental study might help point to
potential underlying mechanisms, which then can be more
specifically tested in genetic epidemiological studies. Finally, the
statistical power of our instrumental variable analysis within the
EPIC-Norfolk cohort was not sufficient to conclude or refute a
potential causal association between the BNP hormone system and
T2D on its own. However, effect estimates of the instrumental
variable analysis and the ordinary regression analysis were
consistent, providing evidence for the validity of observational
results and, hence, for a potential causal association.
Our findings provide insight into the pathophysiology of T2D
by suggesting that the BNP hormone system might have a
protective role, and are in line with existing experimental
evidence. Transgenic mice over-expressing BNP and components
of the BNP downstream signalling cascade were protected from
diet-induced insulin resistance and obesity compared to wild-type
mice, by up-regulation of mitochondrial biogenesis and fat
oxidation [28]. Furthermore, natriuretic peptide receptors are
shown to be expressed in pancreatic beta-cells [29]. An in vitro
study in mice showed that activation of the natriuretic peptide
receptor-A directly modulates pancreatic beta-cell function by
blocking ATP-dependent potassium channel activity, increasing
glucose-elicited Ca
2+ signals, and enhancing glucose-stimulated
insulin secretion in islets of Langerhans [30].
Our findings might have implications for future study by
directing research on exploration of the physiological role of the
BNP and also the ANP hormone system. So far, beyond the
cardiovascular and lipolytic effects, little is known about why a
cardiovascular hormone such as BNP would be physiologically
linked to metabolism. It is well known that BNP is released in
response to physical exercise [31], and thus might contribute to
satisfy the increased energy demand via its lipolytic activity.
However, the physiological background for the link to glucometa-
bolic regulation remains to be determined. Furthermore, the
evidence for a potential causal link between the BNP hormone
system and T2D also promotes BNP as a potentially interesting
target of preventive interventions. Influencing BNP activity by
pharmaceutical interventions has been proven to be feasible in the
context of cardiovascular medicine, e.g., by using recombinant BNP
(Nesiritide) or modifying BNP cleavage and signalling [32,33].
In conclusion, using a Mendelian randomization approach our
study provides evidence for a potential beneficial role of the BNP
hormone system in the aetiology of T2D. Further studies are
needed to explore underlying mechanisms.
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Background. Worldwide, nearly 250 million people have
diabetes, and this number is increasing rapidly. Diabetes is
characterized by dangerous amounts of sugar (glucose) in
the blood. Blood sugar levels are normally controlled by
insulin, a hormone that the pancreas releases after meals
(digestion of food produces glucose). In people with type 2
diabetes (the most common form of diabetes), blood sugar
control fails because the fat and muscle cells that usually
respond to insulin by removing sugar from the blood
become insulin resistant. Type 2 diabetes can be controlled
with diet and exercise, and with drugs that help the pancreas
make more insulin or that make cells more sensitive to
insulin. The long-term complications of diabetes, which
include kidney failure and an increased risk of cardiovascular
problems such as heart disease and stroke, reduce the life
expectancy of people with diabetes by about 10 years
compared to people without diabetes.
Why Was This Study Done? Because the causes of type 2
diabetes are poorly understood, it is hard to devise ways to
prevent the condition. Recently, B-type natriuretic peptide
(BNP, a hormone released by damaged hearts) has been
implicated in type 2 diabetes development in cross-sectional
studies (investigations in which data are collected at a single
time point from a population to look for associations
between an illness and potential risk factors). Although
these studies suggest that high levels of BNP may protect
against type 2 diabetes, they cannot prove a causal link
between BNP levels and diabetes because the study
participants with low BNP levels may share some another
unknown factor (a confounding factor) that is the real cause
of both diabetes and altered BNP levels. Here, the
researchers use an approach called ‘‘Mendelian
randomization’’ to examine whether reduced BNP levels
contribute to causing type 2 diabetes. It is known that a
common genetic variant (rs198389) within the genome
region that encodes BNP is associated with a reduced risk of
type 2 diabetes. Because gene variants are inherited
randomly, they are not subject to confounding. So, by
investigating the association between BNP gene variants
that alter NT-pro-BNP (a molecule created when BNP is being
produced) levels and the development of type 2 diabetes,
the researchers can discover whether BNP is causally
involved in this chronic condition.
What Did the Researchers Do and Find? The researchers
analyzed the association between blood levels of NT-pro-
BNP at baseline in 440 participants of the EPIC-Norfolk study
(a prospective population-based study of lifestyle factors and
the risk of chronic diseases) who subsequently developed
diabetes and in 740 participants who did not develop
diabetes. In this prospective case-cohort study, the risk of
developing type 2 diabetes was associated with lower NT-
pro-BNP levels. They also genotyped (sequenced) rs198389
in the participants of three case-control studies of type 2
diabetes (studies in which potential risk factors for type 2
diabetes were examined in people with type 2 diabetes and
matched controls living in the East of England), and
combined these results with those of eight similar
published case-control studies. Finally, the researchers
showed that the association between rs198389 and type 2
diabetes measured in the case-control studies was similar to
the expected association calculated from the association
between NT-pro-BNP level and type 2 diabetes obtained
from the prospective case-cohort study and the association
between rs198389 and BNP levels obtained from the EPIC-
Norfolk study and other published studies.
What Do These Findings Mean? The results of this
Mendelian randomization study provide evidence for a
causal, protective role of the BNP hormone system in the
development of type 2 diabetes. That is, these findings
suggest that low levels of BNP are partly responsible for the
development of type 2 diabetes. Because the participants in
all the individual studies included in this analysis were of
European descent, these findings may not be generalizable
to other ethnicities. Moreover, they provide no explanation
of how alterations in the BNP hormone system might affect
the development of type 2 diabetes. Nevertheless, the
demonstration of a causal link between the BNP hormone
system and type 2 diabetes suggests that BNP may be a
potential target for interventions designed to prevent type 2
diabetes, particularly since the feasibility of altering BNP
levels with drugs has already been proven in patients with
cardiovascular disease.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001112.
N The International Diabetes Federation provides informa-
tion about all aspects of diabetes
N The US National Diabetes Information Clearinghouse
provides detailed information about diabetes for patients,
health-care professionals, and the general public (in
English and Spanish)
N The UK National Health Service Choices website also
provides information for patients and carers about type 2
diabetes and includes people9s stories about diabetes
N MedlinePlus provides links to further resources and advice
about diabetes (in English and Spanish)
N Wikipedia has pages on BNP and on Mendelian random-
ization (note: Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
N The charity Healthtalkonline has interviews with people
about their experiences of diabetes; the charity Diabetes
UK has a further selection of stories from people with
diabetes
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